Agency Forms Undergoing Paperwork Reduction Act Review, 38096-38097 [2021-15226]
Download as PDF
38096
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices
or to animal or plant products (select
agents and toxins). This joint effort
constitutes the Federal Select Agent
Program. Due to the continuing
pandemic and concerns for the safety of
our workshop attendees and employees,
DSAT replaced in-person workshops
with webinars. The purpose of the
webinars is to provide guidance on
completing APHIS/CDC Form 2
(Request to Transfer Select Agents and
Toxins), APHIS/CDC Form 3 (Report of
a Release/Loss/Theft), and APHIS/CDC
Form 4 (Reporting the Identification of
a Select Agent or Toxin) (APHIS/CDC
Forms 2–4) for interested individuals.
Two sessions covering the same agenda
will be held to provide two
opportunities for interested individuals
to participate.
DATES: The webinars will be held
October 6, 2021 from 10 a.m. to 12:30
p.m. (EDT) and November 3, 2021 from
1:30 p.m. to 4:00 p.m. (EDT).
Registration instructions are found on
the website, https://
www.selectagents.gov.
The webinars will be
conducted from the Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
CDC: Samuel S. Edwin, Ph.D., Director,
DSAT, Center for Preparedness and
Response, CDC, 1600 Clifton Road NE,
MS H–21–7, Atlanta, Georgia 30329.
Telephone: (404) 718–2000; email:
lrsat@cdc.gov. APHIS: Jack Taniewski,
DVM, Director, DASAT, APHIS, 4700
River Road, Unit 2, Riverdale, MD
20737. Telephone: (301) 851–2070;
email: DASAT@usda.gov.
SUPPLEMENTARY INFORMATION: The two
public webinar sessions covering the
same content, scheduled for
Wednesday, October 6, 2021 and
Wednesday, November 3, 2021, are
opportunities for interested individuals
to obtain guidance on completing the
APHIS/CDC Forms 2–4 and reporting
requirements related to the select agent
and toxin regulations (7 CFR part 331,
9 CFR part 121 and 42 CFR part 73). For
individuals not able to attend the
webinars, the information will be
available under the training section at
https://www.selectagents.gov.
Representatives from the Federal
Select Agent Program will be present
during the webinars followed by
question and answer session to address
questions and concerns from the
webinar participants.
Participants who want to participate
in the webinar should complete their
registration online by September 18,
2021. The registration instructions are
lotter on DSK11XQN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
18:23 Jul 16, 2021
Jkt 253001
located on this website: https://
www.selectagents.gov.
Dated: July 14, 2021.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2021–15305 Filed 7–16–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463.
Name of Committee: Safety and
Occupational Health Study Section
(SOHSS), National Institute for
Occupational Safety and Health
(NIOSH).
Dates: October 20–21, 2021.
Time: 11:00 a.m.–5:00 p.m., EDT.
Place: Teleconference.
Agenda: The meeting will convene to
address matters related to the conduct of
Study Section business and for the
study section to consider safety and
occupational health-related grant
applications.
For Further Information Contact:
Michael Goldcamp, Ph.D., Scientific
Review Officer, NIOSH, CDC, 1095
Willowdale Road, Morgantown, WV
26506; Telephone: (304) 285–5951;
Email: mgoldcamp@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–15246 Filed 7–16–21; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–21DC]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled National
Syringe Services Program (SSP)
Evaluation to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on February
25, 2021 to obtain comments from the
public and affected agencies. CDC
received three public comments related
to the previous notice. This notice
serves to allow an additional 30 days for
public and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
E:\FR\FM\19JYN1.SGM
19JYN1
38097
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
National Syringe Services Program
Evaluation—New—National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The primary purpose of the National
Syringe Services Program (SSP)
Evaluation is to strengthen and improve
the capacity of SSPs to conduct regular
monitoring and evaluation to ensure
that comprehensive prevention services
are provided to meet the needs of
people who inject drugs (PWID). The
project will include SSPs that are listed
in a publicly available directory of all
known SSPs in the United States
maintained by the North American
Syringe Exchange Network (NASEN;
https://nasen.org). SSPs will be sent a
letter of invitation to participate in a 35minute program survey, called the Dave
Purchase Memorial Survey.
Participating programs will have the
option of completing the survey via
different modalities to enhance
feasibility and comfort in completing
the survey, for example via the Research
Electronic Data Capture (REDCap) or a
similarly secure web-based application.
Other modalities for survey
administration will include a
coordinated telephone or
videoconferencing interview.
The survey will include questions on
operational characteristics and services,
client characteristics and drug use
patterns, client satisfaction, funding
resources, community relations, and key
operational successes and challenges.
Approximately 600 SSPs will be able to
participate in the survey. We anticipate
that approximately 20% of SSPs will
decline to complete the survey, yielding
approximately 480 completed surveys
per year. However, given that this is the
first survey of SSPs funded by CDC
during the COVID–19 pandemic, it
makes it challenging to predict response
rates. We estimate that it will take 35
minutes to complete the survey,
regardless of how the respondent
chooses to complete it (i.e., selfadministered online or intervieweradministered by phone or
videoconferencing). SSPs that do not
respond to the initial survey invitation
will be given reminders to complete the
survey over the duration of the survey
implementation period. The final
reminder will include a link to a single
question for SSPs that choose not to
complete the survey about why they
declined to complete the survey. Given
the uncertainties in response rates
described above, we are requesting
enough burden hours to allow at least
80% of SSPs to respond to this question.
We estimate that it will take two
minutes to respond to this question.
The total estimated annual burden
hours are 296. There are no other costs
to respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
All participating SSPs .....................................
Non-responding SSPs ....................................
Survey Y1 and Survey Y2–3 .........................
Non-Response Survey Item ...........................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–15226 Filed 7–16–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0070]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
lotter on DSK11XQN23PROD with NOTICES1
Number of
respondents
Type of respondents
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
SUMMARY:
VerDate Sep<11>2014
18:23 Jul 16, 2021
Jkt 253001
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. The meeting will be webcast live
via the World Wide Web. Time will be
available for public comment. A notice
of this ACIP meeting has also been
posted on CDC’s ACIP website at: https://
www.cdc.gov/vaccines/acip/.
In addition, CDC has sent notice of this
ACIP meeting by email to those who
subscribe to receive email updates about
ACIP.
DATES: The meeting will be held on July
22, 2021, from 11:00 a.m. to 4:00 p.m.,
EDT (dates and times subject to change),
see the ACIP website for updates: https://
www.cdc.gov/vaccines/acip/.
The public may submit written
comments from July 19, 2021 through
July 22, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0070 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
480
480
Number of
responses
per
respondent
Average
burden per
response
(hours)
1
1
35/60
2/60
MS H24–8, Atlanta, Georgia 30329–
4027, Attn: July 22, 2021 ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, Georgia 30329–
4027; Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 41 CFR 102–3.150(b),
less than 15 calendar days’ notice is
being given for this meeting due to the
exceptional circumstances of the
COVID–19 pandemic and rapidly
E:\FR\FM\19JYN1.SGM
19JYN1
Agencies
[Federal Register Volume 86, Number 135 (Monday, July 19, 2021)]
[Notices]
[Pages 38096-38097]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15226]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-21DC]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled National Syringe Services Program (SSP)
Evaluation to the Office of Management and Budget (OMB) for review and
approval. CDC previously published a ``Proposed Data Collection
Submitted for Public Comment and Recommendations'' notice on February
25, 2021 to obtain comments from the public and affected agencies. CDC
received three public comments related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open
[[Page 38097]]
for Public Comments'' or by using the search function. Direct written
comments and/or suggestions regarding the items contained in this
notice to the Attention: CDC Desk Officer, Office of Management and
Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
National Syringe Services Program Evaluation--New--National Center
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The primary purpose of the National Syringe Services Program (SSP)
Evaluation is to strengthen and improve the capacity of SSPs to conduct
regular monitoring and evaluation to ensure that comprehensive
prevention services are provided to meet the needs of people who inject
drugs (PWID). The project will include SSPs that are listed in a
publicly available directory of all known SSPs in the United States
maintained by the North American Syringe Exchange Network (NASEN;
https://nasen.org). SSPs will be sent a letter of invitation to
participate in a 35-minute program survey, called the Dave Purchase
Memorial Survey. Participating programs will have the option of
completing the survey via different modalities to enhance feasibility
and comfort in completing the survey, for example via the Research
Electronic Data Capture (REDCap) or a similarly secure web-based
application. Other modalities for survey administration will include a
coordinated telephone or videoconferencing interview.
The survey will include questions on operational characteristics
and services, client characteristics and drug use patterns, client
satisfaction, funding resources, community relations, and key
operational successes and challenges. Approximately 600 SSPs will be
able to participate in the survey. We anticipate that approximately 20%
of SSPs will decline to complete the survey, yielding approximately 480
completed surveys per year. However, given that this is the first
survey of SSPs funded by CDC during the COVID-19 pandemic, it makes it
challenging to predict response rates. We estimate that it will take 35
minutes to complete the survey, regardless of how the respondent
chooses to complete it (i.e., self-administered online or interviewer-
administered by phone or videoconferencing). SSPs that do not respond
to the initial survey invitation will be given reminders to complete
the survey over the duration of the survey implementation period. The
final reminder will include a link to a single question for SSPs that
choose not to complete the survey about why they declined to complete
the survey. Given the uncertainties in response rates described above,
we are requesting enough burden hours to allow at least 80% of SSPs to
respond to this question. We estimate that it will take two minutes to
respond to this question.
The total estimated annual burden hours are 296. There are no other
costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (hours)
----------------------------------------------------------------------------------------------------------------
All participating SSPs................ Survey Y1 and Survey Y2- 480 1 35/60
3.
Non-responding SSPs................... Non-Response Survey Item 480 1 2/60
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-15226 Filed 7-16-21; 8:45 am]
BILLING CODE 4163-18-P